Genetic association of primary nonresponse to anti-TNFα therapy in patients with inflammatory bowel disease

  title={Genetic association of primary nonresponse to anti-TNF$\alpha$ therapy in patients with inflammatory bowel disease},
  author={T. De and H. Zhang and Cristina Alarcon and Bianca Lec and Jose W Avitia and Erin Smithberger and C. B. Chen and Melinda Horv{\'a}th and Sally Kwan and M. M. Young and Sarbani Adhikari and Jennifer Kwon and Jennifer Allen Pacheco and G. P. Jarvik and W.-q. Wei and Frank D. Mentch and Hakon H. Hakonarson and Patrick M A Sleiman and A. S. Gordon and JB Harley and Jessica Beth Linneman and Scott J. Hebbring and Loukia Parisiadou and MA Perera},
  journal={Pharmacogenetics and Genomics},
  pages={1 - 9}
Supplemental Digital Content is available in the text. Objectives Primary nonresponse (PNR) to antitumor necrosis factor-α (TNFα) biologics is a serious concern in patients with inflammatory bowel disease (IBD). We aimed to identify the genetic variants associated with PNR. Patients and methods Patients were recruited from outpatient GI clinics and PNR was determined using both clinical and endoscopic findings. A case-control genome-wide association study was performed in 589 IBD patients and… 
1 Citations
Association of anti-TNF-α treatment with gut microbiota of patients with ankylosing spondylitis
Microbiota dysbiosis in ankylosing spondylitis patients can be restored after anti-TNF-α treatment, possibly by impacting SCFA-producing bacteria.


Novel Genetic Risk Variants Can Predict Anti-TNF Agent Response in Patients With Inflammatory Bowel Disease.
Novel and validated genetic loci, including variants in TNFSF, were found associated with anti-TNF response in patients with IBD, and future validation of the exploratory risk model in a large prospective cohort is warranted.
A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease
The VNTR2/3 genotype in the FcRn gene is associated with lower IFX but also lower adalimumab drug exposure during induction in patients with IBD.
Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn’s Disease
Genetic risk alleles can predict primary non-response and durable response to anti-TNF therapy in CD and a combined clinical and genetics model more accurately predicted PNR when compared with a clinical only model.
Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis
Preliminary evidence suggest effectiveness of infliximab in the treatment of UC, including medically refractory severe disease, however, individuals who are refracted to corticosteroids may be unlikely to respond to inflIXimab.
Management of Primary Nonresponders and Partial Responders to Tumor Necrosis Factor-α Inhibitor Induction Therapy among Patients with Crohn’s Disease
This report summarizes the opinions of 36 Japanese experts attending the Japan Round Table Discussion on IBD Meeting regarding how to determine primary nonresponders (PNR) of TNF-α inhibitors and how to manage these patients in clinical practice.
Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response
  • G. Lichtenstein
  • Medicine, Biology
    Therapeutic advances in gastroenterology
  • 2013
Measurement of anti-TNF agent drug concentrations and assessment of immunogenicity has the potential to positively impact clinical decision making during anti- TNF therapy for IBD, and it is expected that the clinical impact of these determinations will be better characterized.
Disease Activity, ANCA, and IL23R Genotype Status Determine Early Response to Infliximab in Patients With Ulcerative Colitis
The findings suggest that IFX therapy is safe and effective in patients with moderate-to-severe ulcerative colitis and a high CAI before IFX Therapy, ANCA seronegativity, and the IL23R genotype were predictors of early response to IFX.
Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD: Evolution in the Definition and Management of Primary Nonresponse
An overview of this evolution in thinking is described, underpinned by previous findings, and the potential role of early measurement of drug and antidrug antibody concentrations in the definition and management of primary nonresponse is assessed.
High serum tumor necrosis factor-α levels are associated with lack of response to infliximab in fistulizing Crohn's disease
The circulating levels of TNF-α are associated with the response to infliximab and could help to identify patients who would benefit from anti-TNF- α treatment.